HTD1801



NAME OF DRUG : HTD1801

ALSO KNOWN AS : HTD1801

LABORATORY : HighTideTherapeutics

STATUS AND ADVANCEMENT

Type of drug : unknown mechanism of action

Clinical trials advancement : Recruiting Phase 2a

The drug got the Fast Track Status granted by the FDA

Estimated time to market : 98 months.

LABORATORY ABSTRACT ON THE DRUG

Mechanism of Action

Based on available evidence, HTD1801 is fully expected to demonstrate a multi-functional pharmacologic profile targeting multiple aberrant pathways implicated in the pathogenesis of NASH, including the normalization of lipid and glucose metabolism, the reduction of hepatic fat deposition, and hepatocellular protection.

RECENT NEWS ON HTD1801

2018-11-27 : HighTide Therapeutics Receives Fast Track Designation from the U.S. FDA for HTD1801 Treating Nonalcoholic Steatohepatitis (NASH)

SOME PUBLICATIONS RELATED WITH HTD1801

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH HTD1801


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE